ASCO Annual Meeting

ASCO Annual Meeting

Issue: July 25, 2018
June 04, 2018
2 min read

Ribociclib plus fulvestrant improves PFS for advanced breast cancer

Issue: July 25, 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Dennis J . Slamon

CHICAGO — The addition of ribociclib to fulvestrant significantly improved PFS in women with hormone receptor-positive, HER-2-negative advanced breast cancer, irrespective of prior endocrine therapy for advanced disease, according to results of the phase 3 MONALEESA-3 trial presented at the ASCO Annual Meeting.

The data were simultaneously published in Journal of Clinical Oncology.

“In the phase 3 MONALEESA-2 and MONALEESA-7 trials, the addition of ribociclib [Kisqali, Novartis] to endocrine therapy significantly improved PFS compared with placebo plus endocrine therapy in pre-, peri- and postmenopausal women with HR-positive, HER-2-negative advanced breast cancer,” Dennis J . Slamon, MD , PhD, director of clinical/translational research and also director of the Revlon/UCLA Women's Cancer Research Program at UCLA Jonsson Comprehensive Cancer Center, said during his presentation.

“Moreover, CDK4/6 inhibitor and fulvestrant [Faslodex, AstraZeneca] combinations have demonstrated efficacy in patients with hormone receptor-positive breast cancer that has progressed on prior endocrine therapy,” he said. “However, no study had evaluated CDK4/6 inhibitor and fulvestrant combinations in patients with de novo hormone receptor-positive, HER-2-negative advanced breast cancer or in patients who have relapsed more than 1 year after prior endocrine therapy with no subsequent treatment for advanced disease. Until now.”

Slamon and colleagues randomly assigned 726 postmenopausal women in a 2:1 fashion to 600 mg daily ribociclib for 3 weeks on, 1 week off plus 500 mg fulvestrant (n = 484) or placebo plus fulvestrant (n = 242).

PFS served as the study’s primary outcome; secondary outcomes included OS, ORR and safety.

Median duration from randomization to data cutoff was 20.4 months.

Results showed a significant improvement in median PFS with ribociclib (20.5 months vs. 12.8 months; HR = 0.59; 95% CI, 0.48-0.73).

Researchers observed the same treatment effects among women who were treatment naive in the advanced setting (HR = 0.57; 95% CI, 0.41-0.8), and among those treated with up to one line of prior endocrine therapy for advanced disease (HR = 0.56; 95% CI, 0.42-0.74).

In addition, the ORR was higher among women with measurable disease assigned ribociclib vs. placebo (40.9% vs. 28.7%).

Grade 3 adverse events included neutropenia, occurring in 46.6% of patients in the ribociclib arm vs. none in the placebo arm, and leukopenia, occurring in 13.5% of patients in the ribociclib arm vs. none in the placebo arm. – by Jennifer Southall


Slamon DJ, et al. Abstract 1000. Presented at: ASCO Annual Meeting; June 1-5, 2018; Chicago.

Slamon DJ, et al. J Clin Oncol. 2018;doi:10.1200/JCO.2018.78.9909.

Disclosures: Slamon reports a leadership role with BioMarin; stock ownership in Amgen, Pfizer and Seattle Genetics; honoraria from Eli Lily, Novartis and Pfizer; consultant/advisory roles with Eli Lily and Novartis; research funding from Novartis and Pfizer; and payment for travel/accommodations/expenses from Biomarin, Eli Lily, Novartis and Pfizer. Please see the abstract for all other author’s relevant financial disclosures.